Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: A mature follow-up report

Annals of Oncology

Volumn 10, Issue 5, 1999, Pages 605-607

  Fetscher, S ^a   Brugger, W ^b   Engelhardt, S R ^a   Kanz, L ^b   Hasse, J ^a   Frommhold, H ^a   Lange, W ^a   Mertelsmann, R ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hematopoietic growth factors; High dose chemotherapy; Non small cell lung cancer; Peripheral blood stem cell transplantation; Standard dose chemotherapy; Treatment related mortality

Indexed keywords

CARBOPLATIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE;

ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; DRUG MEGADOSE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; EPIRUBICIN; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; SURVIVAL RATE;

EID: 0033014296     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1023/A:1026462707001     Document Type: Article

References (12)

1. Fetscher S, Brugger W, Engelhardt R et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited-and extensive-stage nonsmall-cell lung cancer. Ann Oncol 1997; 8: 57-64.
2. Kaplan EL. Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-61.
3. Mori K., Saitoh Y. Tominage K et al. Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small-cell lung cancer. Eur J Cancer 1993. 5: 677-85.
4. Gomm SA. Thatcher N. Cutherbert A et al. High dose combination chemotherapy with ifosfamide, cyclophosphamide. cisplatin. mitomycin C and mustine with autologous bone marrow support in advanced non-small-cell carcinoma of the lung. Br J Cancer 1991; 63: 293-7.
5. SheaTC. High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer. Cancer Chemother Pharmacol 1997: 40 (Suppl). S74-8.
6. Socinski MA. Shea TC. High-dose therapy with carboplatin and paclitaxel in non-small-cell lung cancer. Semin Oncol 1997; 24 (4. Suppl 12)-S45-S51.
7. Smith IE, Evans B, Harland S et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in treatment of small-cell lung carcinoma. Cancer Chemother Pharmacol 1985; 14: 120-7.
8. Williams SF, Bitran JD, Hoffmann PC et al. High-dose multiplealkylator chemotherapy with autologous bone marrow infusion in patients with advanced non-small-cell lung cancer. Cancer 1989; 63: 238-42.
9. Basade MM, Gulati SC. High-dose chemotherapy with autologous bone marrow/stem-cell rescue in lung cancer. Lancet 1996; 347 (9005): 847-8.
10. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330:153-8.
11. Socinski MA, Shea TC. High-dose therapy with carboplatin and paclitaxel in non-small-cell lung cancer. Semin Oncol 1997; 24 (4, Suppl 12): S45-51.
12. Shea TC High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40 (Suppl): S74-8.